The purpose of the open-label phase 2 ATLAS trial was to assess the safety and efficacy of the PARP inhibitor rucaparib in individuals who have received one or two prior lines of therapy for locally advanced or metastatic urothelial carcinoma.
The study was powered to investigate rucaparib in all-comers (regardless of the presence or not of DNA damage response mutations), but also in the subset of patients with high genome-wide loss of heterozygozity.
Results of the trial were presented by Dr Petros Grivas (Seattle Cancer Care Alliance, WA, USA) at ASCO GU 2020, and do not support use of the PARP inhibitor rucaparib in patients with recurrent, locally advanced, or metastatic urothelial carcinoma.